Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. - Wikidata - wikimedia - TriplyDB

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

http://www.wikidata.org/entity/Q45710733

about

Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children Immunoglobulin treatment for respiratory syncytial virus infection Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Prevention of respiratory syncytial virus infection in infants Respiratory viruses other than influenza virus: impact and therapeutic advances Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis Best practice in the prevention and management of paediatric respiratory syncytial virus infection Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection Recent evidence on the management of bronchiolitis Impact of respiratory syncytial virus: the nurse's perspective Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants Human metapneumovirus in adults Approved Antiviral Drugs over the Past 50 Years The management of acute bronchitis in children Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease.Epidemiological and clinical data of hospitalizations associated with respiratory syncytial virus infection in children under 5 years of age in Spain: FIVE multicenter study Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants Sensitive commercial NASBA assay for the detection of respiratory syncytial virus in clinical specimen A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study.Bronchiolitis.A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy Cost effectiveness of palivizumab in Spain: an analysis using observational data.European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: validation with Italian data.Respiratory Watch: Development of a provincial system for respiratory syncytial virus surveillance in Nova Scotia, 2005-2008.A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations.Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs.Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.Epidemiology of respiratory syncytial virus in various regions within North Carolina during multiple seasons.

P2860

Q24194584-1EA9BF7D-B9ED-4871-8697-07B80C32C6E3 Q24197915-1DD3E6B3-DD0E-4ACD-A018-A27CBFC069D8 Q24202211-2BB4E51F-0B1B-4E0A-A75D-BD773555A18A Q24203706-94B14CD6-77BA-4E01-AD40-624097FDE226 Q24234622-AB0EC879-0A7C-4D25-B2DC-AB10F4EF9A10 Q24235692-13A14ABB-AFAD-4193-8273-D81CD0F9CFFA Q24240074-CE8D3BCE-1036-433B-BCA1-534BD3562407 Q24240702-7315EC60-2E0A-4548-A3EC-6749B1E26C4B Q24561535-650DB3C9-5FF7-447C-9B92-B97C9C686A42 Q24655957-7A60D551-E6BF-4D66-B8BE-DFD1FD986A25 Q26471040-DFB466A9-DF88-4FB5-9C86-ECC74666046B Q26749036-AF74BE6D-AFCF-4AB8-9B19-2C7FB4FF07B5 Q26768419-22E8AF55-3A0D-4E79-A222-F376EC1799A8 Q26825438-7C719317-A9B3-4C0E-9EE6-FEA426751EC2 Q26830864-91005E65-1924-4575-B210-BCC3DA4BB6F8 Q26864494-82C7DBBA-06BA-45EF-BD4B-B2DB68813D2A Q26998906-3CF74500-48D2-481F-ABF5-36CA12F4A445 Q27023799-30EDC1D2-0D2A-41B2-BAF9-CB454E0414A9 Q27027386-3D303EAD-6C32-4ED6-80C3-F4A73550FE30 Q27694039-056A2AAB-CFB1-4BD8-91E0-4C26555F546F Q27755387-127B3819-4CC4-4C2B-B668-2DD296EF69FF Q28288887-30BD577B-E714-4E40-87D9-F07DCCE7EE62 Q30245434-6C8675CC-FCFD-4ABE-A80B-65E3FEF05533 Q30725005-24F59CDC-695D-4B44-AE2C-C59D0EE28C6C Q31047460-3847298D-C002-465B-81D7-E72ABCC14F84 Q33312377-14B627BE-E855-4D7F-9113-38B0157C6C81 Q33390780-96D62A9F-EF6D-4651-BE0F-A17A80C567D4 Q33446856-2E04D360-9420-4F51-AAF3-19D9FA0842FA Q33478019-A9746CBF-8D1E-47DE-9D18-846D33AEF4CE Q33501862-88E35C74-4B1C-4B1A-87AF-8940FF968143 Q33517462-0D2A7F7D-D1DB-4B9C-9817-9072B31422A7 Q33582499-FDAC88A0-AF8A-49EB-A100-4B022A3425AC Q33593708-B9BC9A32-1318-4D5C-AA0E-8B777E4148F0 Q33595073-5728EB14-6DBF-4331-90A7-AA93720E62AB Q33596700-C34F8B5B-6599-41A4-8BF2-2E5DF95DFBD1 Q33705088-E3B822A9-8D24-4F3F-8797-E1B5EAB3C808 Q33714072-31D15686-C215-41F8-9418-7C85CF9B00D0 Q33723350-A172BB56-0132-47F9-AEBB-BC85324CD87E Q33724997-0BC8E12F-D494-4895-9985-B4481463C4FC Q33828343-2FE804BD-BE7D-4C6D-9BAE-5FFC90D90BA7

P2860

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.

http://www.wikidata.org/entity/Q45710733

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Palivizumab prophylaxis reduce ...... cant congenital heart disease.

@en

Palivizumab prophylaxis reduce ...... cant congenital heart disease.

@nl

type

label

Palivizumab prophylaxis reduce ...... cant congenital heart disease.

@en

Palivizumab prophylaxis reduce ...... cant congenital heart disease.

@nl

prefLabel

Palivizumab prophylaxis reduce ...... cant congenital heart disease.

@en

Palivizumab prophylaxis reduce ...... cant congenital heart disease.

@nl

P1433

Q45710733-B0BF6C31-41BD-4F3F-B06D-E3AFE958A616

P1476

Q45710733-B551B1A3-F97B-420F-B6EA-C1AEFEBDF24B

P2093

Q45710733-06958AE6-98DE-4470-8CBD-46ADAA8344CE

Q45710733-3A15F957-B537-4751-BE4A-4D86E4253327

Q45710733-55558809-CC05-49BD-8403-C36AC1CFDDC3

Q45710733-660E4967-5209-4D69-8E98-5B731878786C

Q45710733-92DE1D8B-E453-41E1-8794-2ECFD893636B

Q45710733-A9FFB95C-932C-4EC2-AEE1-F4884BF8E36A

Q45710733-DE06563B-4F03-4DCE-8EC8-3D82223757CB

Q45710733-DF2C0F45-3F32-4906-89D3-485938D3DDDD

Q45710733-FB6DB92C-93D2-4857-9BE0-631AE13A5B5D

P304

Q45710733-09124518-112A-4B68-A2D6-B12E75CC7796

P31

Q45710733-D4FA1E93-6BBE-4B6C-A609-A573A7D8CF67

P356

Q45710733-E9669155-79B6-4DFD-B912-EAA2B03243B3

P407

Q45710733-BE020D32-D038-4B08-8A59-89AF0EDB1DD7

P433

Q45710733-C24A0BFF-C208-4C81-84D9-56443E055C49

P478

Q45710733-0B05D115-3F37-4EE1-A6DD-29AA816ECED2

P577

Q45710733-7418448C-7A04-4FE9-8A3A-1AFAD7FC9879

P698

Q45710733-F4B538E3-DEA0-478E-9ACE-3CB0360FFD47

P921

Q45710733-1083DDA3-D28B-4001-8324-F728984F6506

Q45710733-38713267-2D33-4BD2-8820-6FD85CF5B3F1

P356

S0022-3476(03)00454-2

P1433

The Journal of Pediatrics

P1476

Palivizumab prophylaxis reduce ...... cant congenital heart disease.

@en

P2093

Allison K Cabalka

http://www.w3.org/2001/XMLSchema#string

Cardiac Synagis Study Group

http://www.w3.org/2001/XMLSchema#string

David A Carlin

http://www.w3.org/2001/XMLSchema#string

Edward M Connor

http://www.w3.org/2001/XMLSchema#string

Franco M Piazza

http://www.w3.org/2001/XMLSchema#string

Franklin H Top

http://www.w3.org/2001/XMLSchema#string

H Cody Meissner

http://www.w3.org/2001/XMLSchema#string

Henry M Sondheimer

http://www.w3.org/2001/XMLSchema#string

Timothy F Feltes

http://www.w3.org/2001/XMLSchema#string

P304

532-540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/S0022-3476(03)00454-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14571236

http://www.w3.org/2001/XMLSchema#string

P921

hospitalization